NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis $27.49 +0.30 (+1.10%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$27.39▼$27.7050-Day Range$24.85▼$28.4852-Week Range$24.53▼$39.53Volume424,553 shsAverage Volume590,089 shsMarket Capitalization$18.18 billionP/E Ratio22.91Dividend YieldN/APrice Target$49.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Genmab A/S alerts: Email Address Genmab A/S MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside80.1% Upside$49.50 Price TargetShort InterestBearish0.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 13 Articles This WeekInsider TradingN/AProj. Earnings Growth24.78%From $1.13 to $1.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.75 out of 5 starsMedical Sector220th out of 924 stocksPharmaceutical Preparations Industry89th out of 426 stocks 4.2 Analyst's Opinion Consensus RatingGenmab A/S has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 8 buy ratings, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageGenmab A/S has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Genmab A/S's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.45% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Genmab A/S has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GMAB. Previous Next 2.0 News and Social Media Coverage News SentimentGenmab A/S has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Genmab A/S this week, compared to 4 articles on an average week.Search InterestOnly 12 people have searched for GMAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsOnly 7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Genmab A/S are expected to grow by 24.78% in the coming year, from $1.13 to $1.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 22.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 22.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 133.84.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.01. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. Click here to get details on this opportunity now. About Genmab A/S Stock (NASDAQ:GMAB)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMAB Stock News HeadlinesAugust 21 at 4:39 AM | americanbankingnews.comGenmab A/S's (GMAB) Buy Rating Reaffirmed at HC WainwrightAugust 20 at 11:34 PM | markets.businessinsider.comBuy Rating Affirmed for Genmab Following Epcoritamab’s European Approval and Strong Pipeline PotentialAugust 22, 2024 | Porter & Company (Ad)This technology could swing the electionHidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.August 20 at 8:10 AM | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by JPMorgan Chase & Co.August 19 at 2:00 PM | globenewswire.comTEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaAugust 17, 2024 | americanbankingnews.comShort Interest in Genmab A/S (NASDAQ:GMAB) Increases By 33.3%August 17, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives Average Recommendation of "Hold" from AnalystsAugust 16, 2024 | globenewswire.comGenmab Announces Changes to its Executive CommitteeAugust 22, 2024 | Porter & Company (Ad)This technology could swing the electionHidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.August 13, 2024 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsAugust 13, 2024 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseAugust 13, 2024 | americanbankingnews.comFY2025 EPS Estimates for Genmab A/S Decreased by Analyst (NASDAQ:GMAB)August 13, 2024 | americanbankingnews.comGenmab A/S to Post Q3 2024 Earnings of $0.28 Per Share, William Blair Forecasts (NASDAQ:GMAB)August 12, 2024 | seekingalpha.comGenmab A/S 2024 Q2 - Results - Earnings Call PresentationAugust 12, 2024 | americanbankingnews.comGenmab A/S's (GMAB) Buy Rating Reiterated at HC WainwrightAugust 12, 2024 | marketwatch.comGenmab A/SAugust 9, 2024 | finanznachrichten.deGenmab A/S: Genmab Updates 2024 Financial GuidanceAugust 8, 2024 | globenewswire.comGenmab Announces Financial Results for the First Half of 2024See More Headlines Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today8/22/2024Next Earnings (Confirmed)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GMAB CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees2,204Year Founded1999Price Target and Rating Average Stock Price Target$49.50 High Stock Price Target$53.00 Low Stock Price Target$47.00 Potential Upside/Downside+80.1%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$1.20 Trailing P/E Ratio22.91 Forward P/E Ratio24.33 P/E Growth1.01Net Income$631.91 million Net Margins30.74% Pretax Margin39.74% Return on Equity18.90% Return on Assets16.83% Debt Debt-to-Equity RatioN/A Current Ratio12.46 Quick Ratio12.42 Sales & Book Value Annual Sales$19.02 billion Price / Sales0.96 Cash Flow$1.20 per share Price / Cash Flow22.87 Book Value$6.95 per share Price / Book3.96Miscellaneous Outstanding Shares661,299,000Free Float651,115,000Market Cap$18.18 billion OptionableOptionable Beta0.97 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.9MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.03MMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.14MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $637.57kMr. Christopher Cozic (Age 45)Executive VP & Chief People Officer Comp: $782.47kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $695.53kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $115.92kDr. Judith V. Klimovsky M.D. (Age 66)Executive VP & Chief Development Officer Comp: $1.17MDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.12MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $159.39kMore ExecutivesKey CompetitorsTakeda PharmaceuticalNYSE:TAKModernaNASDAQ:MRNATeva Pharmaceutical IndustriesNYSE:TEVABioNTechNASDAQ:BNTXBeiGeneNASDAQ:BGNEView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Bought 18,184 shares on 8/19/2024Ownership: 0.003%Creative PlanningSold 16,761 shares on 8/16/2024Ownership: 0.003%Millennium Management LLCSold 92,934 shares on 8/15/2024Ownership: 0.058%Cubist Systematic Strategies LLCBought 145,689 shares on 8/14/2024Ownership: 0.042%Bank of Montreal CanSold 1,803 shares on 8/14/2024Ownership: 0.012%View All Institutional Transactions Should I Buy Genmab A/S Stock? GMAB Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Genmab A/S: Genmab A/S has a strong average rating of "Hold" from analysts, indicating stability in the company's performance. Recent price target updates from analysts suggest a potential upside of 76.37% from the current stock price, providing a growth opportunity for investors. Institutional investors have been increasing their stakes in Genmab A/S, indicating confidence in the company's future prospects. Genmab A/S has a market capitalization of $18.75 billion, reflecting the company's significant size and presence in the market. The company's 12-month low of $24.53 provides a potential entry point for investors looking to buy at a lower price. Cons Investors should be bearish about investing in Genmab A/S for these reasons: Despite some positive analyst ratings, there are still sell recommendations on the stock, indicating potential risks associated with investing in Genmab A/S. The stock has been trading down recently, showing a 1.0% decrease, which may raise concerns about short-term performance. Genmab A/S has a beta of 0.97, suggesting that the stock's price is closely correlated with market movements, potentially leading to higher volatility. The company's P/E ratio of 23.58 may indicate that the stock is currently overvalued compared to its earnings, posing a risk for investors. Genmab A/S has a 1-year high of $39.81, which could signal resistance at higher price levels and limit potential short-term gains for investors. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 19, 2024. Please send any questions or comments about these Genmab A/S pros and cons to contact@marketbeat.com. GMAB Stock Analysis - Frequently Asked Questions How have GMAB shares performed this year? Genmab A/S's stock was trading at $31.84 at the beginning of the year. Since then, GMAB stock has decreased by 13.7% and is now trading at $27.49. View the best growth stocks for 2024 here. How were Genmab A/S's earnings last quarter? Genmab A/S (NASDAQ:GMAB) posted its quarterly earnings data on Wednesday, November, 10th. The company reported $0.21 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.10. The company earned $366.25 million during the quarter, compared to the consensus estimate of $341.46 million. Genmab A/S had a trailing twelve-month return on equity of 18.90% and a net margin of 30.74%. When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Top institutional shareholders of Genmab A/S include Renaissance Technologies LLC (0.22%), Envestnet Asset Management Inc. (0.15%), Marshall Wace LLP (0.10%) and American Century Companies Inc. (0.07%). How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC) and Pfizer (PFE). This page (NASDAQ:GMAB) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
